Yunnan Baiyao Group Co Ltd
SZSE:000538

Watchlist Manager
Yunnan Baiyao Group Co Ltd Logo
Yunnan Baiyao Group Co Ltd
SZSE:000538
Watchlist
Price: 58.08 CNY -2.44% Market Closed
Market Cap: 102.8B CNY
Have any thoughts about
Yunnan Baiyao Group Co Ltd?
Write Note

Yunnan Baiyao Group Co Ltd
Gain/Loss on Disposition of Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Yunnan Baiyao Group Co Ltd
Gain/Loss on Disposition of Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gain/Loss on Disposition of Assets CAGR 3Y CAGR 5Y CAGR 10Y
Yunnan Baiyao Group Co Ltd
SZSE:000538
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Gain/Loss on Disposition of Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Gain/Loss on Disposition of Assets
-ÂĄ286.3k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Yunnan Baiyao Group Co Ltd
Glance View

Market Cap
103.6B CNY
Industry
Pharmaceuticals

Yunnan Baiyao Group Co Ltd is a well-established Chinese healthcare company renowned for its pioneering products in traditional Chinese medicine, particularly in wound care and pain management. With a rich history dating back to 1902, the company originally gained fame for its unique powder that promotes blood circulation and aids in healing. Over the years, Yunnan Baiyao has evolved into a comprehensive healthcare provider, offering a diverse range of products that span over-the-counter medications, personal care items, and even high-tech medical devices. Its commitment to innovation, backed by a robust research and development framework, has positioned it as a leader in the market, appealing to both traditional and modern healthcare consumers. From an investment standpoint, Yunnan Baiyao stands out as a compelling opportunity due to its strong brand recognition and growing market share in a rapidly expanding healthcare sector. The company consistently showcases impressive financial performance, characterized by robust revenue growth and sustainable profit margins. With the rising demand for effective treatment options fueled by an aging population and increasing health awareness in China, Yunnan Baiyao is strategically positioned to capture this opportunity. As it continues to diversify its product lines and expand internationally, investors may find Yunnan Baiyao to be a promising company that embodies the principles of resilience and adaptability, traits that Warren Buffett and Charlie Munger have long advocated in value investing.

Intrinsic Value
67.17 CNY
Undervaluation 14%
Intrinsic Value
Price

See Also

Back to Top